Tetratherix Begins Tetramatrix Product Revenue With First US Shipment

MT Newswires Live

Yesterday

Tetratherix (ASX:TTX) made its first commercial shipment of Tetramatrix polymer to the US under its Precision Medicine partnership with Superpower Health, adding product revenue to its existing $3 million annual license fee, according to a Monday filing with the Australian bourse.

The shipment follows successful US export clearance, commercial-scale manufacturing, and the US Food and Drug Administration's assignment of a unique identifier to the company's STEPP polymer platform, per the filing.

The company also said a peer-reviewed study on its PNPHO polymer for intranasal semaglutide delivery was accepted by the International Journal of Pharmaceutics, independently validating the technology and its potential for peptide drug delivery, the filing added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/news/2663618023"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2663618023\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2663618023?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-31 08:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2663618023","market":"hk","top_or_hot":-1,"title":"Tetratherix Begins Tetramatrix Product Revenue With First US Shipment","media":"MT Newswires Live","content":"<html><body><p> Tetratherix (ASX:TTX) made its first commercial shipment of Tetramatrix polymer to the US under its Precision Medicine partnership with Superpower Health, adding product revenue to its existing $3 million annual license fee, according to a Monday filing with the Australian bourse.</p><p>The shipment follows successful US export clearance, commercial-scale manufacturing, and the US Food and Drug Administration's assignment of a unique identifier to the company's STEPP polymer platform, per the filing.</p><p>The company also said a peer-reviewed study on its PNPHO polymer for intranasal semaglutide delivery was accepted by the International Journal of Pharmaceutics, independently validating the technology and its potential for peptide drug delivery, the filing added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tetratherix Begins Tetramatrix Product Revenue With First US Shipment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTetratherix Begins Tetramatrix Product Revenue With First US Shipment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-31 08:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Tetratherix (ASX:TTX) made its first commercial shipment of Tetramatrix polymer to the US under its Precision Medicine partnership with Superpower Health, adding product revenue to its existing $3 million annual license fee, according to a Monday filing with the Australian bourse.</p><p>The shipment follows successful US export clearance, commercial-scale manufacturing, and the US Food and Drug Administration's assignment of a unique identifier to the company's STEPP polymer platform, per the filing.</p><p>The company also said a peer-reviewed study on its PNPHO polymer for intranasal semaglutide delivery was accepted by the International Journal of Pharmaceutics, independently validating the technology and its potential for peptide drug delivery, the filing added.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2663618023","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2663618023","pubTimestamp":1788137454,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tetratherix  made its first commercial shipment of Tetramatrix polymer to the US under its Precision Medicine partnership with Superpower Health, adding product revenue to its existing $3 million annual license fee, according to a Monday filing with the Australian bourse.The shipment follows successful US export clearance, commercial-scale manufacturing, and the US Food and Drug Administration's assignment of a unique identifier to the company's STEPP polymer platform, per the filing.The company also said a peer-reviewed study on its PNPHO polymer for intranasal semaglutide delivery was accepted by the International Journal of Pharmaceutics, independently validating the technology and its potential for peptide drug delivery, the filing added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","TTX.AU":"Tetratherix Ltd"},"translate_title":"Tetratherix 首次在美国发货，开始实现 Tetramatrix 产品收入","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TTX.AU":1},"content_text":"Tetratherix (ASX:TTX) made its first commercial shipment of Tetramatrix polymer to the US under its Precision Medicine partnership with Superpower Health, adding product revenue to its existing $3 million annual license fee, according to a Monday filing with the Australian bourse.The shipment follows successful US export clearance, commercial-scale manufacturing, and the US Food and Drug Administration's assignment of a unique identifier to the company's STEPP polymer platform, per the filing.The company also said a peer-reviewed study on its PNPHO polymer for intranasal semaglutide delivery was accepted by the International Journal of Pharmaceutics, independently validating the technology and its potential for peptide drug delivery, the filing added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}